The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure
Abstract
OBJECTIVES: To examine whether endogenous aldosterone can cause either arrhythmias (and some of their underlying mechanisms) or endothelial dysfunction in patients with coronary artery disease (CAD) but without heart failure. BACKGROUND: Aldosterone blockade has been shown to reduce the incidence of sudden death in patients with heart failure. This could be caused by a reduction in arrhythmias or in coronary events. Whether either effect also occurs in other cardiac patients without heart failure is currently unknown. METHOD: We performed a randomized, placebo-controlled, double-blind crossover study on 98 patients with CAD but without heart failure on standard therapy, comparing 12.5-50 mg/day spironolactone (3 months) with placebo. Endothelial function was assessed by bilateral forearm venous occlusion plethysmography. Ventricular extrasystoles, procollagen III N-terminal peptide (PIIINP) and QT interval length were used to represent arrhythmias and their determinants. RESULTS: Spironolactone produced a highly significant 75% reduction in ventricular extrasystoles (median 192, range 48-744) on placebo compared with spironolactone (median 48, range 19.2-288, P < 0.003). Spironolactone also decreased the QT interval from a mean of 440 +/- 28 to a mean of 425 +/- 25 (P < 0.001) and a collagen marker (PIIINP) from a mean of 3.6 +/- 0.9 to a mean of 3.0 +/- 0.8 (P < 0.001), but did not significantly change endothelial dysfunction or heart rate variability. CONCLUSION: These results suggest that despite conventional therapy, endogenous aldosterone can be an arrhythmogenic influence in patients with CAD, but without heart failure. The possible mechanisms are that aldosterone promotes myocardial fibrosis and lengthens the QTc interval as well as decreasing potassium in CAD patients without heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, spironolactone, an MR antagonist, has been shown to decrease QTc in populations vulnerable to cardiac arrythmia (20).”
From Effect of Hypoglycemia on QT Interval in Individuals With and Without Type 2 Diabetes: A Randomized Crossover Trial (2025) · cites this paper as [20]
Citations
Cites
Heart Rate Variability: Standards of Measurement, Physiological Interpretation, and Clinical Use
Electrophysiology, T. F. O. T. E. S. O. C. T. N. A. (1996) · Circulation · doi:10.1161/01.cir.93.5.1043 · Cited by 17,159
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Zannad, F., Alla, F., Dousset, B., Perez, A., & Pitt, B. (2000) · Circulation · doi:10.1161/01.cir.102.22.2700 · Cited by 947
Farquharson, C. A. J., & Struthers, A. D. (2000) · Circulation · doi:10.1161/01.cir.101.6.594 · Cited by 532
Self-citationAllopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Self-citationMeasuring Forearm Blood Flow and Interpreting the Responses to Drugs and Mediators
Benjamin, N., Calver, A., Collier, J., Robinson, B., Vallance, P., & Webb, D. (1995) · Hypertension · doi:10.1161/01.hyp.25.5.918 · Cited by 399
Spironolactone Improves Angiotensin-Induced Vascular Changes and Oxidative Stress
Virdis, A., Neves, M. F., Amiri, F., Viel, E., Touyz, R. M., & Schiffrin, E. L. (2002) · Hypertension · doi:10.1161/01.hyp.0000034738.79310.06 · Cited by 399
Pitt, B., White, H., Nicolau, J., Martinez, F., Gheorghiade, M., Aschermann, M., van Veldhuisen, D. J., Zannad, F., Krum, H., Mukherjee, R., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.038 · Cited by 388
Arntz, H. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1739 · Cited by 361
Cited by
Feingold, B., Mahle, W. T., Auerbach, S., Clemens, P., Domenighetti, A. A., Jefferies, J. L., Judge, D. P., Lal, A. K., Markham, L. W., Parks, W. J., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000526 · Cited by 306
Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases
López, B., González, A., & Díez, J. (2010) · Circulation · doi:10.1161/circulationaha.109.912774 · Cited by 252
Tomaschitz, A., Pilz, S., Ritz, E., Meinitzer, A., Boehm, B. O., & Marz, W. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq019 · Cited by 171
Cubeddu, L. X. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160301120217 · Cited by 157
Role of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
Ferrario, C. M., & Schiffrin, E. L. (2014) · Circulation Research · doi:10.1161/circresaha.116.302706 · Cited by 105
Metadata
- Authors
- Shah, N. C., Pringle, S. D., Donnan, P. T., & Struthers, A. D.
- Affiliations
- Ninewells Hospital (GB)
- Corresponding author
- Struthers, Allan D
- Venue
- Journal of Hypertension
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 2345-2351
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2038607077
- Cited by
- 43
- References
- 27
- Citations by year
- 2026: 2 · 2025: 1 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 5 · 2014: 6 · 2013: 1 · 2012: 2
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Funders
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Keywords
- spironolactone, aldosterone blockade, coronary artery disease, ventricular arrhythmias, premature ventricular contractions, QT interval, endothelial dysfunction, myocardial fibrosis, potassium, antiarrhythmic effect
- MeSH terms
- Aged, Aldosterone, Mineralocorticoid Receptor Antagonists, Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Double-Blind Method, Electrocardiography, Female, Forearm, Humans, Male, Middle Aged, Peptide Fragments, Procollagen, Spironolactone, Myocardial Ischemia, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. https://app.cochat.ai/papers/10.1097/hjh.0b013e3282e9a72d
- The paper
- Shah, N. C., Pringle, S. D., Donnan, P. T., & Struthers, A. D. (2007). Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. Journal of Hypertension. https://doi.org/10.1097/hjh.0b013e3282e9a72d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.